scholarly journals Influence of Angiotensin-Converting Enzyme Inhibitors (ACEi) on Angiogenesis Induced by Physical Exercise

2021 ◽  
Vol 23 (4) ◽  
pp. 306-310
Author(s):  
Anderson Geremias Macedo ◽  
David Michel de Oliveira ◽  
André Thiago Rosito Goes ◽  
Astor Reis Simionato ◽  
Danyelle Siqueira Miotto ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Physical Exercise ◽  
Enzyme Inhibitors ◽  
Blood Pressure Reduction ◽  
Sulfhydryl Group ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Reduce Blood Pressure ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Ace Activity

AbstractAngiotensin-converting enzyme inhibitors (ACEi) are used to reduce blood pressure and vascular resistance by modulating the ACE activity responsible for the angiotensin II formation. However, different ACEi seem to influence exercise-induced angiogenesis. The objective of this review was to investigate the effects of different ACEi on vessel growth in skeletal muscle induced by exercise training. The present study is characterized by a narrative literature review design, the databases of Scielo, Google Scholar and PubMed were consulted. There are different groups of ACEi , sulfhydryl group such as captopril and a carboxyl group such as perindiporil and enalapril that can influence their effects on ACE activity. It is already known that exercise promotes the increase of vessels from vessels already existing in the skeletal musculature, a process known as angiogenesis and contributes to the blood pressure reduction (BP). Although these different responses are still scarce, vessel endothelial growth factor (VEFG) and nitric oxide (NO) may participate. Thus, the use of different ACEi can influences the angiogenesis responses induced by exercise, being one of the important mechanisms for BP reduction. The choice of ACEi group should be carefully analyzed for hypertensive individuals who practice physical exercise. Keywords: Physical Education and Training. Microcirculation. Hypertension. ResumoOs inibidores da enzima conversora de angiotensina (iECA) são utilizados para redução da pressão arterial e resistência vascular modulando a atividade da ECA responsável pela formação da angiotensina II. Entretanto, diferentes iECAs parecem influenciar a angiogênese induzida pelo exercício físico. Desta maneira objetivo desta revisão foi investigar os efeitos de diferentes iECA sobre o crescimento de vasos no musculo esquelético induzido pelo exercício físico. O presente estudo caracteriza-se um delineamento de revisão de literatura narrativa, foram consultadas as bases de dados do Scielo, Google acadêmico e PubMed. Existem grupos distintos dos iECAs, grupo sulfidrila como o captopril e o grupo carboxila como o perindiporil e grupo que pode influenciar seus efeitos sobre a atividade da ECA. Já é sabido que O exrcício promove o aumento de vasos a partir de vasos já existentes na musculatura esquelética, processo conhecido como angiogênese e colabora para redução da pressão arterial (PA). Entretanto os iECAs parecem influenciar esta resposta do aumento da densidade capilar no músculo esquelético. Embora ainda sejam escassos estas diferentes respostas podem ter as participações do fator de crescimento endotelial de vasos (VEFG) e o óxido nítrico (NO). Desta maneira o uso dos grupos do iECAs podem influenciar as resposta da angiogênese induzido pelo exercício sendo um dos mecanismos importantes pela redução da PA. A escolha do grupo de iECA deve ser analisada com cautela para indivíduoS hipertensos que praticam exercício físico. Palavras-chave: Educação Física e Treinamento. Microcirculação. Hipertensão

scholarly journals Optimization of treatment of hypertension in hypothyroidism: the role and place of angiotensin-converting enzyme inhibitors

2008 ◽  
Vol 14 (3) ◽  
pp. 270-274
Author(s):  
G. Selivanova
Keyword(s):  
Blood Pressure ◽  
Enzyme Inhibitors ◽  
Blood Pressure Reduction ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Pressure Reduction ◽  
Converting Enzyme ◽  
Thyroid Status ◽  
Converting Enzyme Inhibitors ◽  
Treatment Of Hypertension ◽  
Hypothyroid Patients

The study addresses antihypertensive therapy in 60 hypothyroid patients with hypertension of different degrees. It is documented that 70% of hypertensive in patients with sub compensation of hypothyroidism have stage 3 hypertension. The efficacy of perindopril in these patients is 87,5%. The time necessary for blood pressure reduction is longer in patients with older age, severe hypertensions and lower thyroid status.

Dangers of Captopril Therapy in Newborns

PEDIATRICS ◽  
1989 ◽  
Vol 83 (6) ◽  
pp. 1076-1076
Author(s):  
VIVIAN REZNIK ◽  
WILLIAM GRISWOLD ◽  
STANLEY MENDOZA
Keyword(s):  
Blood Pressure ◽  
Renal Failure ◽  
Angiotensin Converting Enzyme ◽  
Premature Infant ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Treatment Of Hypertension

Angiotensin-converting enzyme inhibitors are effective at lowering blood pressure in the neonate and the child. However, these drugs, when used for the treatment of hypertension in the premature infant, must be used with caution to avoid the complications that are well documented in the literature. All of the infants described in the article by Perlman and Volpe had extreme hypotension and oligunia. A group of nine infants with renal failure complicating captopril therapy were recently reported from the same institution.

scholarly journals Prediction Models of Albumin Renal Excretion in Type 2 Diabetes Mellitus Patients

2019 ◽  
Vol 70 (11) ◽  
pp. 3802-3807
Author(s):  
Amorin Remus Popa ◽  
Claudia Teodora Judea Pusta ◽  
Cosmin Mihai Vesa ◽  
Simona Bungau ◽  
Camelia Liana Buhas ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Positive Correlation

Microalbuminuria is a cardiovascular risk factor in type 2 diabetes mellitus patients. It is very important to know which the predictor factors for albuminuria are, because these elements may be influenced by pharmacological measures. In our study we propose three models for the prediction of albumin glomerular excretion in a group of 446 type 2 diabetes mellitus patients: the clinical-biochemical model, the pharmacological model, and the integrative model that reunites the two models. In the clinical-biochemical model, albumin excretion was statistically significant influenced by HbA1c (positive correlation) and blood pressure (positive correlation). In the pharmacological model, albumin excretion was influenced by angiotensin converting enzyme inhibitors or angiotensin II receptor blockers treatment (negative correlation). In the integrative model, the factors were HbA1c (positive correlation), diastolic blood pressure (positive correlation), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers treatment (negative correlation) and statins treatment (negative correlation). The prevalence of microalbuminuria was 16.14 %. Patients with microalbuminuria had statistically significant higher values of HbA1c, systolic blood pressure, diastolic blood pressure, triglycerides and lower values of HDL-cholesterol. A low glucose control was the most important risk factor for an increased albumin glomerular elimination. The importance of our study consists in the fact that all the elements that predict albuminuria can be influenced: HbA1c, blood pressure, therapy with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers and statins.

Domestic practice of antihypertensive treatment of diabetic hypertensive patients

2014 ◽  
Vol 155 (43) ◽  
pp. 1695-1700
Author(s):  
Veronika Szentes ◽  
Gabriella Kovács ◽  
Csaba András Dézsi
Keyword(s):  
Blood Pressure ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Beta Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Patients With Diabetes

Diabetes mellitus as comorbidity is present in 20–25% of patients suffering from high blood pressure. Because simultaneous presence of these two diseases results in a significant increase of cardiovascular risk, various guidelines focus greatly on the anti-hyperintensive treatment of patients with diabetes. Combined drug therapy is usually required to achieve the blood pressure target value of <140/85 mmHg defined for patients with diabetes, which must be based on angiotensin converting enzyme-inhibitors or angiotensin receptor blockers. These can be/must be combined with low dose, primarily thiazid-like diuretics, calcium channel blockers with neutral metabolic effect, and further options include the addition of beta blockers, imidazolin-l-receptor antagonists, or alpha-1-adrenoreceptor blockers. Evidence-based guidelines are obviously present in local practice. Although most of the patients receive angiotensin converting enzyme-inhibitor+indapamid or angiotensin converting enzyme-inhibitor+calcium channel blocker combined therapy with favorable metabolic effects, yet the use of angiotensin converting enzyme-inhibitors containing hidrochlorotiazide having diabetogenic potencial, and angiotensin receptor blocker fixed combinations is still widespread. Similarly, interesting therapeutic practice can be observed with the use of less differentiated beta blockers, where the 3rd generation carvediolol and nebivolol are still in minority. Orv. Hetil., 2014, 155(43), 1695–1700.

Sign in / Sign up

Export Citation Format

Share Document